Sanofi: FDA issues Complete Response Letter for Zynquista(TM) (sotagliflozin)

Sanofi Media Relations Contact Nicolas Kressmann Tel.: +1 732-532-5318mr@sanofi.com Lexicon Media Relations Contact Chas Schultz Tel.: +1-281-863-3421cschultz@lexpharma.com Sanofi Investor Relations Contact George Grofik Tel.: +33 (0)1 53 77 45 45ir@sanofi.com Lexicon Investor Relations Contact Kimberly Lee, D.O. Tel: +1 281-863-3383klee@lexpharma.com Sanofi Forward-Looking StatementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, ...

Gepostet in der Kategorie Wirtschaft (Anzahl der ansichten:) 4

Ähnlich Nachrichten